AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24473673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate (add-on strategy)
Number of subjects: 556
Study 24473673 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab plus placebo (switch strategy)
Number of subjects: 556
Study 21068025 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose weekly paclitaxel (80 mg/m² initially followed by 100 and 120 mg/m² unless severe toxicity is observed)
Number of subjects: 90
Study 21068025 — intervention group
Group type: COMPARATOR
Intervention: Standard dose weekly paclitaxel (80 mg/m²)
Number of subjects: 90
Study 19362232 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced chiropractor
Number of subjects: 50
Study 19362232 — intervention group
Group type: COMPARATOR
Intervention: Inexperienced chiropractic student
Number of subjects: 50
Study 17537155 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress SPECT with a low dose of TcTF (296 MBq)
Number of subjects: 222
Study 17537155 — intervention group
Group type: COMPARATOR
Intervention: Combined stress and rest SPECT using TlCl (111 MBq)
Number of subjects: 222
Study 14966079 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors' perception of patient pressure
Number of subjects: 847
Study 14966079 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived medical need
Number of subjects: 847
Study 14966079 — intervention group
Group type: COMPARATOR
Intervention: Examination
Number of subjects: 847
Study 14966079 — intervention group
Group type: COMPARATOR
Intervention: Prescription
Number of subjects: 847
Study 14966079 — intervention group
Group type: COMPARATOR
Intervention: Referral
Number of subjects: 847
Study 14966079 — intervention group
Group type: COMPARATOR
Intervention: Investigation
Number of subjects: 847
Study 11452245 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg oral clarithromycin twice daily for 4 days
Number of subjects: 9
Study 11452245 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg oral clarithromycin
Number of subjects: 9
Study 11452245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9639610 — intervention group
Group type: EXPERIMENTAL
Intervention: Operations supported by randomised controlled trials (RCTs)
Number of subjects: 49
Study 9639610 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evident interventions
Number of subjects: 49
Study 9639610 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised prospective or retrospective studies
Number of subjects: 49
Study 9639610 — intervention group
Group type: EXPERIMENTAL
Intervention: Operations not supported by substantial evidence
Number of subjects: 49
Study 8028383 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 50
Study 8028383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 50
Study 8028383 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 50
Study 8028383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 50
Study 8028383 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 2915441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prochlorperazine edisylate (10 mg)
Number of subjects: 82
Study 2915441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2-mL intravenous injection of sterile saline solution)
Number of subjects: 82
Study 1107772 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg, three times a day for three weeks)
Number of subjects: 18
Study 1107772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30683076 — intervention group
Group type: EXPERIMENTAL
Intervention: Savings account offer bundled with health services
Number of subjects: 1800
Study 30683076 — intervention group
Group type: COMPARATOR
Intervention: Health services alone
Number of subjects: 1800
Study 27881389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 92
Study 27881389 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 92
Study 27881389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 25793222 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 40
Study 25793222 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 40
Study 23418877 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG:HSA
Number of subjects: 24
Study 23418877 — intervention group
Group type: COMPARATOR
Intervention: ICG alone
Number of subjects: 24
Study 21080183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency NMES (LF-NMES) at 15 Hz
Number of subjects: 17
Study 21080183 — intervention group
Group type: COMPARATOR
Intervention: High-frequency NMES (HF-NMES) at 75 Hz
Number of subjects: 17
Study 19829040 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dartos flap (monolayer group)
Number of subjects: 77
Study 19829040 — intervention group
Group type: COMPARATOR
Intervention: Double dartos flap (double flap group)
Number of subjects: 77
Study 16723655 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (test group)
Number of subjects: 334
Study 16723655 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (control group)
Number of subjects: 334
Study 15291994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus epinephrine
Number of subjects: 60
Study 15291994 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 60
Study 11473324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stents (3 stents over 1 year)
Number of subjects: 34
Study 11473324 — intervention group
Group type: COMPARATOR
Intervention: Control group (selective pancreatograms, no stent)
Number of subjects: 34
Study 11473324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stents
Number of subjects: 34
Study 11473324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 9626923 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole for 7 days
Number of subjects: 7
Study 9626923 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 7
Study 7909822 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine levels
Number of subjects: 859
Study 7909822 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin activity
Number of subjects: 859
Study 7909822 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin
Number of subjects: 859
Study 7909822 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide
Number of subjects: 859
Study 7909822 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular venous pressure and third heart sound (S3) gallop
Number of subjects: 859
Study 3586502 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (100 mmol/day for 10 days)
Number of subjects: 35
Study 3586502 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (before potassium supplementation)
Number of subjects: 35
Study 30170011 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital devices
Number of subjects: 215
Study 30170011 — intervention group
Group type: COMPARATOR
Intervention: Analog devices
Number of subjects: 215
Study 25633239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemfola(®)
Number of subjects: 32
Study 25633239 — intervention group
Group type: COMPARATOR
Intervention: Gonal‐f(®)
Number of subjects: 32
Study 25419886 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and mHealth intervention
Number of subjects: 20
Study 21953326 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching intervention (telephone counseling at least three times over 6 months)
Number of subjects: 15
Study 21953326 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching intervention
Number of subjects: 15
Study 21609915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 63
Study 21609915 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive agents (Control)
Number of subjects: 63
Study 18534636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally complete liquid meal (1256 kJ)
Number of subjects: 19
Study 18534636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior and dietary intervention
Number of subjects: 19
Study 15900367 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (HMG) at a dose rate of 150 IU/day from day 3 of the cycle
Number of subjects: 154
Study 15900367 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) agonist at a dose rate of 800 microg/day by nasal spray or 500 microg/day subcutaneously in the mid-luteal phase, followed by standard HMG dose after pituitary down regulation
Number of subjects: 154
Study 15900367 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene at a dose rate of 100 mg/day from day 3 and HMG from day 6
Number of subjects: 154
Study 14620319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5% Abbocaine) applied to the right tonsillar fossa
Number of subjects: 72
Study 14620319 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.9%) applied to the left tonsillar fossa (Control)
Number of subjects: 72
Study 11008912 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 A Day method
Number of subjects: 260
Study 11008912 — intervention group
Group type: COMPARATOR
Intervention: Summation method
Number of subjects: 260
Study 11008912 — intervention group
Group type: COMPARATOR
Intervention: 24‐h dietary recalls
Number of subjects: 260
Study 11008912 — intervention group
Group type: COMPARATOR
Intervention: Food records
Number of subjects: 260
Study 9066739 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision plus isolated hyperthermic limb perfusion (IHLP) using melphalan at 2 mg/kg body weight (n = 16)
Number of subjects: 30
Study 9066739 — intervention group
Group type: COMPARATOR
Intervention: Excision (control, n = 14)
Number of subjects: 30
Study 8350327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (im) gold plus 3 im injections of 120 mg methylprednisolone acetate
Number of subjects: 40
Study 8350327 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (im) gold plus placebo
Number of subjects: 40
Study 8350327 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (glucocorticoid and gold only)
Number of subjects: 40
Study 3088664 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg twice a day
Number of subjects: 9
Study 3088664 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 20 mg twice a day
Number of subjects: 9
Study 3088664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29398672 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 12,000 IU
Number of subjects: 198
Study 29398672 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 6,000 IU
Number of subjects: 198
Study 29398672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 27315415 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving program delivered by physical and occupational therapy practitioners, including a structured interview and an education and resource packet.
Number of subjects: 287
Study 27315415 — intervention group
Group type: COMPARATOR
Intervention: Resource packet only (Control group).
Number of subjects: 287
Study 25106493 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion (IHP)
Number of subjects: 78
Study 25106493 — intervention group
Group type: COMPARATOR
Intervention: Best alternative care (BAC)
Number of subjects: 78
Study 23219490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay Attention! intervention (16 bi-weekly sessions)
Number of subjects: 105
Study 23219490 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 105
Study 20861424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mg/mL at 2 mL/h for 24 hours
Number of subjects: 38
Study 20861424 — intervention group
Group type: COMPARATOR
Intervention: Saline at 2 mL/h for 24 hours
Number of subjects: 38
Study 18683195 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol plus vitamin C
Number of subjects: 42
Study 18683195 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C only
Number of subjects: 42
Study 16372192 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis (maximum of 50 mg rtPA injected into the ophthalmic artery)
Number of subjects: 200
Study 16372192 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (bulbus massage, topical beta-blocker, acetazolamide, acetylsalicylic acid, heparin, isovolemic hemodilution)
Number of subjects: 200
Study 12781927 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized form (PF) letter containing generic cancer information
Number of subjects: 1574
Study 12781927 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized tailored (PT) letter containing minimally tailored individualized risk factor information
Number of subjects: 1574
Study 12781927 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1574
Study 10899723 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg clarithromycin (CLA)
Number of subjects: 15
Study 10899723 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg clarithromycin (CLA)
Number of subjects: 15
Study 10899723 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg clarithromycin (CLA)
Number of subjects: 15
Study 10899723 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg clarithromycin (CLA)
Number of subjects: 15
Study 10899723 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 15
Study 8646825 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol perfused at varying rates (not specified) over 160 minutes into different parts of the small intestine.
Number of subjects: 6
Study 8646825 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol perfusion rates lower than 600 micrograms/min.
Number of subjects: 6
Study 8646825 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol perfusion at higher rates in the distal region compared to the proximal small intestine.
Number of subjects: 6
Study 8646825 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol oral bioavailability.
Number of subjects: 6
Study 31333763 — intervention group
Group type: EXPERIMENTAL
Intervention: iPhone level function of the Measure application
Number of subjects: 21
Study 31333763 — intervention group
Group type: COMPARATOR
Intervention: Digital inclinometer
Number of subjects: 21
Study 31333763 — intervention group
Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 21
Study 30030269 — intervention group
Group type: EXPERIMENTAL
Intervention: FR (fludarabine plus rituximab)
Number of subjects: 342
Study 30030269 — intervention group
Group type: EXPERIMENTAL
Intervention: FR + L (fludarabine plus rituximab plus lenalidomide consolidation)
Number of subjects: 342
Study 30030269 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR (fludarabine plus cyclophosphamide and rituximab)
Number of subjects: 342
Study 26696461 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive Seed Localization (RSL)
Number of subjects: 125
Study 26696461 — intervention group
Group type: COMPARATOR
Intervention: Wire Localization (WL)
Number of subjects: 125
Study 24529061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirapazamine and cisplatin
Number of subjects: 63
Study 24529061 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and 5FU
Number of subjects: 63
Study 22201185 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment strategy (ARS) with 10 consecutive breaths at a plateau pressure of 40 and 20 cm H(2)O PEEP applied immediately before and after OLV.
Number of subjects: 40
Study 22201185 — intervention group
Group type: COMPARATOR
Intervention: Control group with tidal volume (VT) of 8 or 6 ml kg(‐1) for TLV and OLV, respectively.
Number of subjects: 40
Study 18535542 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recalls (24E)
Number of subjects: 60
Study 18535542 — intervention group
Group type: COMPARATOR
Intervention: Previous day morning interviews (PDM)
Number of subjects: 60
Study 18535542 — intervention group
Group type: EXPERIMENTAL
Intervention: Social desirability
Number of subjects: 60
Study 18535542 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of stretches, internal confabulations, and external confabulations
Number of subjects: 60
Study 17037003 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 50
Study 17037003 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 50
Study 12969588 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic rollerball electrocoagulation (RBE)
Number of subjects: 139
Study 12969588 — intervention group
Group type: COMPARATOR
Intervention: Uterine balloon thermal ablation (Thermachoice)
Number of subjects: 139
Study 10877166 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day cefixime (8 mg/kg/day given once daily followed by 3 days of placebo)
Number of subjects: 36
Study 10877166 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day cefixime
Number of subjects: 36
Study 9261912 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation
Number of subjects: 0
Study 9261912 — intervention group
Group type: EXPERIMENTAL
Intervention: Moment-based estimation
Number of subjects: 0
Study 9261912 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent methods with repeated measurements
Number of subjects: 0
Study 8415813 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose prostaglandin E1 (PGE1) infusion (0.02 microgram kg‐1 min‐1)
Number of subjects: 20
Study 8415813 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20
Study 3534859 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 to 50 mg b.i.d.)
Number of subjects: 15
Study 3534859 — intervention group
Group type: COMPARATOR
Intervention: Increasing doses of frusemide (25 to 100 mg o.d.)
Number of subjects: 15
Study 29730130 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention (EI)
Number of subjects: 70
Study 29730130 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 70
Study 27254028 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 27254028 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study 24115138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1600 IU and calcium carbonate 1000 mg (D+)
Number of subjects: 150
Study 24115138 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate alone (D‐)
Number of subjects: 150
Study 23477160 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Xiatianwu combined with methotrexate (MTX)
Number of subjects: 104
Study 23477160 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 104
Study 23477160 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Compound Xiatianwu + MTX and MTX)
Number of subjects: 104
Study 19930776 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mometasone furoate nasal spray for six weeks
Number of subjects: 60
Study 19930776 — intervention group
Group type: COMPARATOR
Intervention: Self-adjusted regimen of mometasone furoate nasal spray (daily for one week, every alternate day for one week, then self-adjusted for four weeks)
Number of subjects: 60
Study 19930776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (daily and self-adjusted)
Number of subjects: 60
Study 18303031 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP staging system
Number of subjects: 538
Study 18303031 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO performance status (PS)
Number of subjects: 538
Study 18303031 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-fetoprotein for BCLC
Number of subjects: 538
Study 18303031 — intervention group
Group type: COMPARATOR
Intervention: Okuda staging system
Number of subjects: 538
Study 18303031 — intervention group
Group type: COMPARATOR
Intervention: BCLC staging system
Number of subjects: 538
Study 17000388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free repair (TFR)
Number of subjects: 641
Study 17000388 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (WW)
Number of subjects: 641
Study 14603198 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies
Number of subjects: 427
Study 11452855 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography (CTA)
Number of subjects: 86
Study 11452855 — intervention group
Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 86
Study 8627643 — intervention group
Group type: COMPARATOR
Intervention: Bolus 5-FU at 500 mg/m2 for 5 days followed in 2 weeks by weekly bolus 5-FU at 600 mg/m2 (Treatment A)
Number of subjects: 497
Study 8627643 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU at 300 mg/m2 per day by continuous infusion (Treatment C)
Number of subjects: 497
Study 8627643 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU at 300 mg/m2 per day by continuous infusion plus weekly cisplatin at 20 mg/m2 (Treatment D)
Number of subjects: 497
Study 8627643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus 5-FU at 500 mg/m2 for 5 days followed in 2 weeks by weekly bolus 5-FU at 600 mg/m2 plus weekly cisplatin at 20 mg/m2 (Treatment B)
Number of subjects: 497
Study 1471698 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 9
Study 1471698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6362905 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/day clonidine for 3 days
Number of subjects: 29
Study 6362905 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg iv naloxone
Number of subjects: 29
Study 6362905 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with naloxone
Number of subjects: 29
Study 6362905 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine treatment with naloxone
Number of subjects: 29
Study 29590362 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail individuals
Number of subjects: 1280
Study 29590362 — intervention group
Group type: EXPERIMENTAL
Intervention: Very frail individuals
Number of subjects: 1280